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G-protein-coupled receptors (GPCRs) mediate many important physiological functions and are considered as one of the most success-
ful therapeutic targets for a broad spectrum of diseases.  The design and implementation of high-throughput GPCR assays that allow 
the cost-effective screening of large compound libraries to identify novel drug candidates are critical in early drug discovery.  Early 
functional GPCR assays depend primarily on the measurement of G-protein-mediated 2nd messenger generation.  Taking advantage of 
the continuously deepening understanding of GPCR signal transduction, many G-protein-independent pathways are utilized to detect 
the activity of GPCRs, and may provide additional information on functional selectivity of candidate compounds.  With the combination 
of automated imaging systems and label-free detection systems, such assays are now suitable for high-throughput screening (HTS).  In 
this review, we summarize the most widely used GPCR assays and recent advances in HTS technologies for GPCR drug discovery.
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Introduction
G-protein-coupled receptors (GPCRs), also known as 7 trans-
membrane receptors, are the largest family of cell surface 
receptors and account for approximately 4% of the protein-
coding human genome
[1].  They are activated by a wide variety 
of stimulants, including light, odorant molecules, peptide and 
non-peptide neurotransmitters, hormones, growth factors and 
lipids, and control a wide variety of physiological processes 
including sensory transduction, cell–cell communication, neu-
ronal transmission, and hormonal signaling.  
After agonist binding, activated receptors catalyze the 
exchange of guanidine diphosphate (GDP) for guanidine 
triphosphate (GTP) on the α-subunit of heterotrimeric G 
proteins (composed of α-, β-, and γ-subunits), which in turn 
engages conformational changes that lead to the dissociation 
of Gα from the dimeric Gβγ subunits
[2].  GPCRs coupled to 
Gαs and Gαi/o proteins activate or inhibit, respectively, adeny-
late cyclase, the enzyme responsible for converting adenosine 
triphosphate (ATP) to 3’,5’-cyclic adenosine monophosphate 
(cAMP).  cAMP serves as a second messenger that activates 
protein kinase A (PKA) and other downstream effectors (pre-
viously reviewed
[3]).  GPCRs coupled to Gαq/o alternatively 
activate phospholipase Cβ (PLCβ), which catalyzes the forma-
tion of diacylglycerol (DAG) and inositol-1,4,5-trisphosphate 
(IP3).  IP3 then binds and opens the endoplasmic IP3-gated 
calcium channel, causing the release of calcium into the cyto-
plasm.  GPCRs coupling to Gα12/13 further activate the guanine 
nucleotide exchange factor RhoGEF, which in turn activates 
the small G protein RhoA.  
In the presence of continuous agonist stimulation, GPCRs 
are phosphorylated by specific GPCR kinases (GRKs), and 
the recruitment of β-arrestins to the phosphorylated GPCRs 
eventually terminates G protein signaling and leads to a coor-
dinated process of receptor desensitization, inactivation and 
internalization
[3].  The β-arrestins also facilitate the forma-
tion of multi-molecular complexes and provide a means for 
G protein-independent signaling of GPCRs, including those 
involving mitogen-activated protein (MAP) kinases, recep-
tor and non-receptor tyrosine kinases, phosphatidylinositol 
3-kinases (PI3K) and others
[4].
Given their importance in health and disease, together with 
their potential for therapeutic intervention via using small 
molecules as regulators, GPCRs represent the largest family of 
druggable targets.  These receptors are the target of >50% of 
the current therapeutic agents on the market, including more 
than a quarter of the 100 top-selling drugs, with profits in the 
range of several billion US dollars each year
[5].  Therefore, 
GPCR assay development and GPCR ligand screening remain 
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the major focus of drug discovery research worldwide.  His-
torically, radioligand binding assays with receptor-containing 
membranes were used to identify compounds that target 
GPCRs.  However, binding affinity data do not tell us whether 
the compound is an agonist or an antagonist, or more impor-
tantly, the overall potency of a compound under physiological 
conditions.  Efforts have been made in the past few decades 
to develop signaling-dependent cell-based functional assays 
to provide more accurate and comprehensive data of the com-
pounds targeting GPCRs.  
An ideal assay for GPCR ligand screening should be simple, 
nonradioactive, robust, homogenous, and easily adapted to 
a microtiter plate format (96-, 384-, or 1536-well) for robotic 
automation.  Since GPCR signaling consists of a series of spa-
tial and temporal events, another important consideration is 
whether to measure a proximal or distal signaling step after 
GPCR stimulation.  Measurement of events proximal to recep-
tor activation will reduce the incidence of false positives
[6]; 
however, moving down the signal transduction cascade will 
enhance the signal-to-noise ratio due to signal amplifica-
tion.  Many GPCRs also activate multiple signaling pathways.   
Biased signaling, a phenomenon in which certain agonists 
display better efficacies in activating one pathway over oth-
ers, is another critical issue to consider in functional screen 
development
[4, 7].  If a functional assay capturing only one 
signaling pathway is selected for screening compound librar-
ies, potentially valuable compounds could be missed if the 
compound does display biased activity.  Therefore, multiplex-
ing of signaling pathways or assays representing an overall 
cellular response may be used to resolve such problems.  In 
this review, we summarize the most widely used GPCR assays 
and recent advances in high-throughput screening (HTS) tech-
nology for GPCR drug discovery (Table 1).
Receptor binding assay
Receptor binding assay can be used to characterize in great 
detail the interaction between receptor and its ligands, such as 
the intrinsic affinity of ligands to the receptor, association/dis-
sociation rates, and the density of receptor in tissues or cells
[8].   
Receptor binding assay is a cell-free method theoretically suit-
able for any GPCR screening without involving downstream 
signaling from the receptor.  This type of assay can also obtain 
agonists and antagonists in one experiment, but without dis-
tinguishing whether the candidate compound is an agonist, 
antagonist, or inverse agonist.  However, the availability of 
labeled ligands greatly limits the application of this assay.  It is 
practically useless for GPCR deorphanization.  
The first radioligand binding assay was performed in 1970 
by Lefkowitz et al using a radiolabeled hormone to deter-
mine the binding affinity for its receptor
[9].  Since then, 
3H- 
or 
125I-labeled ligands have been widely used to characterize 
the affinity of a compound for a target GPCR, while non-
labeled compounds can be characterized by their ability to 
displace the binding of a radiolabeled molecule to the target 
(orthosteric agonists/antagonists) or to modulate the affinity 
of a radiolabeled molecule for the target (some allosteric mod-
ulators)
[10].  The traditional radioligand binding assays require 
washing and filtration steps, which can only be scaled down 
to a 96-well format.  
A homogenous scintillation proximity assay (SPA), which 
can be easily scaled down and automated for HTS applica-
tions, was developed more recently (reviewed in
[11]).  In SPA, 
only the radiolabeled molecules binding to the GPCR immobi-
lized on the surface of SPA beads can activate the scintillation 
beads, which produce photons detectable with a scintillation 
counter.  SPA thus allows binding reactions to be tested with-
out washing or filtration steps.  Although radioligand binding 
gives a clear, unmistakable signal, radioligands are relatively 
expensive, problematic to dispose of, and some isotopes have 
inconveniently short half-lives.  These drawbacks have led to 
the creation of highly sensitive nonradioactive alternatives.
Many new binding assays are based on time-resolved fluo-
rescence resonance energy transfer (TR-FRET) technology, 
such as DELFIA
TM TRF from PerkinElmer, the LanthaScreen
TM 
system from Invitrogen, and the Tag-lite
TM system from Cisbio.   
Tag-lite
TM is a newly developed homogeneous time-resolved 
fluorescence (HTRF) technology
[12] for assaying GPCR ligand 
binding in HTS format.  A suicide enzyme (either SNAP- or 
CLIP-tag) is fused to the N-terminus of a GPCR without affect-
ing its binding and activity, and a non-permeant substrate 
labeled with terbium cryptate fluorophore (Lumi4-Tb) is used 
to specifically and covalently label the receptors expressed 
on the cell surface.  The ligands are labeled with red or green 
acceptors.  The long fluorescence lifetime of the terbium 
cryptate allows a time-resolved measurement of FRET emis-
sion when all natural fluorescence disappears.  The assay is 
carried out in a “mix and measure” format, which can be used 
not only for ligand binding studies but also for receptor activ-
ity analysis and GPCR dimerization assessment (as discussed 
below).  The availability of Tagged-GPCR expressing cell lines 
and the fluorophore-labeled ligands are some of the limita-
tions in this approach.
G-protein dependent functional assays
Ligand-binding assays are useful to identify new compounds 
that target GPCRs.  Further analysis of the biological responses 
after compound binding will help complete the whole picture 
concerning the overall characteristics of the compound.  Upon 
ligand binding, GPCRs change their conformation and activate 
coupled G proteins, which subsequently promote second mes-
senger production via downstream effectors.  The correspond-
ing assays measuring either G protein activation or G protein-
mediated events, including second messenger generation 
and reporter activation, are therefore defined as G-protein-
dependent functional assays (Figure 1).
GTPγS binding assay
GTPγS binding assays directly measure the guanine nucle-
otide exchange of G proteins, an early event after GPCR acti-
vation, which is not subjected to amplification or regulation by 
other cellular processes
[6].  Typically, the accumulation of non-
hydrolysable GTP analog, such as [
35S]-GTPγS, on the plasma 374
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membrane prepared from cells expressing GPCRs of interest 
is measured after agonist stimulation.  Unlike receptor bind-
ing assays, the GTPγS binding assay allows discrimination 
between full or partial agonists, neutral antagonists, inverse 
agonists, and allosteric regulators
[13].  In reality, this assay is 
experimentally more feasible for receptors coupled to Gαi/o, 
which is the most abundant G protein in many cells and has a 
faster GDP-GTP exchange rate than other G proteins
[6].  Nev-
ertheless, [
35S]-GTPγS binding assays can also be used with 
GPCRs that couple to the Gαs and Gαq families of G proteins, 
especially in artificial expression systems, or using receptor-Gα 
chimeras, or by immunoprecipitation of [
35S]-GTPγS-labeled 
Gα (reviewed in
[13]).  A problem with this assay is that it 
requires a filtration step through glass fiber to separate free 
and bound [
35S]-GTPγS, which limits assay throughput.  With 
the development of SPA technology, the filtration step can be 
omitted and GTPγS binding assays can be adopted for high-
throughput screening
[14, 15].  
With the increased desire to move assays to a non-radio- 
active format, a GTP binding assay based on time-resolved 
fluorescence (TRF) technology utilizing a non-radioactive, 
non-hydrolysable, europium-labeled GTP analog, GTP-Eu, 
has been developed for GPCR screening (DELFIA
TM GTP 
binding assay from PerkinElmer)
[16].  However, this assay still 
requires filtration and washing steps.  The DELFIA
TM GTP 
binding assay has been validated on several GPCRs, includ-
ing α2-adrenergic
[17], neuropeptide FF2 receptor
[18], dopamine 
D3 receptor
[19] and muscarinic receptors
[20], and the results are 
comparable with those obtained using traditional [
35S]-GTPγS 
binding assays
[21].
cAMP assay
Assays measuring cellular levels of cAMP are dependent on 
the activity of adenylyl cyclase, which is regulated by GPCRs 
coupled to Gαs or Gαi/o protein.  Gαs positively stimulates 
the activity of adenylate cyclase, resulting in increased cel-
lular cAMP.  In contrast, activation of Gαi leads to a negative 
regulation of adenylate cyclase and a decrease in cAMP levels.   
Screening Gαs-coupled receptors is generally straightforward, 
whereas screening Gαi/o-coupled receptors, especially for 
Gαi/o-coupled receptor antagonists, could be extremely dif-
ficult to achieve with high precision using cAMP detection 
methods.  This difficulty arises because of the requirement to 
pre-stimulate adenylate cyclase with forskolin, which should 
be titrated during assay optimization, to inhibit the response 
with agonist and then measure reversal of the agonist effect 
with antagonists.  In addition, to counteract the natural 
degradation of cAMP to AMP by phosphodiesterase (PDE) 
enzymes, an inhibitor of PDE (eg, IBMX) might be required in 
the system during assay optimization.  cAMP levels are typi-
cally measured using a competition assay in which cellular 
cAMP competes with an introduced, labeled form of cAMP for 
binding to an anti-cAMP antibody.  
Radiometric assays, such as the SPA cAMP assay from GE 
Healthcare and the FlashPlate
TM cAMP assay from Perkin-
Elmer using 
125I-labeled cAMP, are widely used.  More 
recently, these assays have been replaced with fluorescence- 
or luminescence-based homogenous assays to avoid the use of 
radioactivity.  There are several newer radio-free approaches 
for cAMP detection.  One such assay is based on Enzyme Frag-
ment Complementation (HitHunter
TM) and was introduced 
by DiscoveRx (http://www.discoverx.com).  Cellular cAMP 
competes with cAMP labeled with a small peptide fragment 
of β-galactosidase for binding to an anti-cAMP antibody.  The 
resulting free labeled-cAMP complements with the enzyme 
fragment, producing active β-galactosidase, which is detected 
with fluorescent or luminescent substrates
[22, 23].  AlphaScreen
TM 
from PerkinElmer is a sensitive bead-based proximity chemi-
luminescent assay.  Cellular cAMP competes with a biotiny-
lated cAMP probe recognized by a streptavidin donor and 
anti-cAMP antibody-conjugated acceptor beads.  Release of 
the biotinylated cAMP from the antibody results in the dis-
sociation of the streptavidin donor from its acceptor, which 
can be measured as a decrease in the chemiluminescent signal 
(http://www.perkinelmer.com).  In addition, fluorescence 
polarization (FP)-based cAMP kits are available from Perkin-
Elmer, Molecular Devices and GE Healthcare.  When exposed 
to polarized light, the emission from an antibody-bound 
fluorescent-labeled cAMP is also polarized due to restricted 
molecular rotation.  When the labeled cAMP is replaced on the 
antibody by cellular cAMP, the emission becomes more depo-
larized because it can rotate freely in solution.  With the avail-
ability of red-shifted fluorophores, the signal-to-noise ratios 
have been greatly improved
[24].  Furthermore, HTRF-based 
cAMP detection is available from Cisbio.  With this method, 
novel donor (cAMP antibody labeled with europium cryptate) 
and acceptor (cAMP labeled with a modified allophycocyanin 
dye) pairs are designed to increase the stability of the signal 
and make this assay highly sensitive and reproducible for 
cAMP measurement
[12].  Finally, the cAMP Glosensor
TM assay 
is a luciferase biosensor-based assay from Promega
[25].  Upon 
cAMP binding, the conformational change in the biosensor 
leads to the activation of luciferase and increased light output.   
Figure 1.  Receptor binding and G-protein-dependent assays.  Schematic 
representation of receptor binding and major pathways activated by 
different G proteins.  Red indicates the detection points of commonly used 
HTS assays: GTPγS binding, cAMP detection, IP3/IP1 detection, Ca
2+ flux 
and reporter expression.376
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This type of assay can be used to measure GPCR function in 
a non-lytic live-cell format, enabling facile kinetic measure-
ments of cAMP accumulation or turnover in living cells.  The 
assay also offers a broad dynamic range, showing up to 500-
fold changes in light output.  Extreme sensitivity allows the 
detection of Gαi-coupled receptor activation or inverse agonist 
activity in the absence of artificial stimulation by compounds 
such as forskolin (http://www.promega.com/glosensor).  A 
direct comparison of AlphaScreen
TM, HTRF, HitHunter
TM, and 
FP cAMP assays suggests that there are advantages and dis-
advantages in each method
[26].  The AlphaScreen
TM and HTRF 
assays are recommended for cells expressing low levels of 
GPCRs because of their higher sensitivities.  
IP3/IP1 and Ca
2+ assays
Stimulation of Gαq or Gαi coupled-GPCRs activates phos-
pholipase C (PLC), which hydrolyzes phosphatidylinositol 
bisphosphate (PIP2) to form two second messengers, inosi-
tol 1,4,5-triphosphate (IP3) and DAG.  While DAG activates 
protein kinase C (PKC), IP3 activates the IP3 receptor on the 
endoplasmic reticulum (ER) resulting in an efflux of Ca
2+ from 
the ER to the cytoplasm and an elevation of intracellular Ca
2+.   
IP3 is very rapidly hydrolyzed to IP2, then to IP1 and finally 
to inositol by a series of enzymatic reactions
[27].  The radioac-
tive IP3 assay measures 
3H-inositol incorporation and is a 
traditional assay for the assessment of PLC activity, but it is 
not suitable for the screening of large compound collections 
because it requires a cell wash step and generates radioactive 
waste.  An SPA platform has been developed to achieve higher 
throughput and homogenous assays in measuring IP accumu-
lation.  
There are a few non-radiometric technologies used for the 
measurement of IP3, including AlphaScreen™ (PerkinElmer) 
and HitHunter™ Fluorescence Polarization (DiscoveRx) 
assay.  Recently, a homogeneous, non-radioactive TRF assay 
for measuring IP accumulation, IP-One HTRF™, was released 
by Cisbio (http://www.htrf.com).  The basis for the assay 
is a reduction in energy transfer between acceptor IP1 and a 
europium-conjugated IP1 antibody as cellular IP1 accumulates 
and replaces the acceptor IP1 in binding the IP1 antibody.   
Compared to earlier kits using IP3-binding proteins to specifi-
cally measure IP3, the IP-One assay takes advantage of the fact 
that LiCl inhibits the degradation of IP1, the final step in the 
inositol phosphate cascade, allowing it to accumulate in the 
cell and to be measured as a substitute for IP3.  This assay also 
does not require a kinetic readout.  Data reported by Cisbio 
show that the assay can be used with endogenously or heter-
ologously expressed GPCRs in either adherent or suspension 
cells to quantitate the activity of agonists, antagonists, and 
inverse agonists.  Additionally, the efficacy data from the IP-
One assay correlate well with those from calcium assays and 
traditional IP3 assays (http://www.htrf.com).  This assay can 
be adopted for ultra high-throughput screening in the 1536-
well plate format and has been tested with cell lines express-
ing M1 acetylcholine, FFAR1, vasopressin V1b, and neuropep-
tide S receptors
[28].
As previously mentioned, intracellular Ca
2+ is another sec-
ond messenger for GPCR signaling.  GPCRs that naturally 
couple to Gαq produce a ligand-dependent increase in intra-
cellular Ca
2+.  However, Gαi/o, Gαs, or Gα12-coupled GPCRs 
can also be “switched” to induce an increase in intracellular 
Ca
2+ either by the expression of a chimeric G-protein (Gαqi5 or 
Gαqo5) or a promiscuous G-protein (Gα16 or Gα15) (reviewed 
in
[29]).  The Ca
2+ assay is very popular in GPCR screening 
owing to the availability of cell-permeable Ca
2+-sensitive fluo-
rescent dyes (such as Fluo-3 and Fluo-4) and automated real-
time fluorescence plate readers, such as FLIPR™ from Molecu-
lar Device.  Molecular Device also offers fluorescent dye kits, 
which contain proprietary quenching molecules that allow cel-
lular loading of dye without the need of subsequent cell wash-
ing to remove excess dye
[30].  The integrated pipetting capabili-
ties of the FLIPR™ allow ultra high-throughput screening in 
384- or 1536-well format with the ability to detect agonists, 
antagonists, and allosteric modulators all in one assay.  The 
use of fluorescent dyes can also be replaced by the use of Ca
2+-
sensitive biosensors.  Recombinant expression of the jellyfish 
photoprotein aequorin, which provides an intense luminescent 
signal in response to elevated intracellular Ca
2+ in the pres-
ence of a coelenterazine derivative, has also been developed 
for functional screens of GPCRs
[31].  With the overexpression 
of promiscuous G-proteins, the Ca
2+ assay does not require the 
prior knowledge of G protein coupling conditions and signal-
ing pathways of the receptor, so it is widely used to de-orphan 
GPCRs
[32, 33].  
Although Ca
2+ assays are robust and easily amenable to 
HTS, there are some important shortcomings.  They cannot be 
used to screen for inverse agonists because increases in basal 
Ca
2+ are not observed in cells expressing constitutively active 
Gαq-coupled receptors.  In addition, calcium flux occurs rap-
idly and transiently and is not suitable to detect slow binding 
agonists.  In such conditions, an IP1 accumulation assay will 
be more useful.  Furthermore, false positive signals obtained 
from fluorescent and nuisance compounds are a problem, and 
the sensitivity is often insufficient to allow the use of primary 
cells.  
Reporter assay
GPCR activation is well known to alter gene transcription 
via responsive elements for second messengers including the 
cAMP response element (CRE), the nuclear factor of activated 
T-cells response element (NFAT-RE), the serum response 
element (SRE) and the serum response factor response ele-
ment (SRF-RE, a mutant form of SRE), all of which are located 
within the gene promoter regions (reviewed in
[34]).  Therefore, 
cell-based reporter assays provide another popular and cost-
effective HTS platform for GPCR screening.  Reporter gene 
constructs usually contain second messenger responsive ele-
ments upstream of a minimal promoter, which in turn regu-
late the expression of a selected reporter protein.  Commonly 
used reporters are enzyme proteins with activities linked to a 
variety of colorimetric, fluorescent or luminescent readouts, 
such as luciferase, alkaline phosphatase, β-galactosidase, 377
www.chinaphar.com
Zhang R et al
Acta Pharmacologica Sinica
npg
β-lactamase and a variety of fluorescent proteins.  Among 
them, luciferase is the reporter of choice, especially in high-
throughput screening due to its sensitivity, broad dynamic 
range, lack of endogenous activity and low interference com-
ing from the compounds
[35].  
The advantages of reporter gene assays include the wide 
linearity and sensitivity of the technique and a large signal-
to-background ratio, making them suitable for the detection 
of weak GPCR agonists or allosteric modulators.  Reporter 
gene assays are also easy to set up and can be scaled down to 
extremely low assay volumes in 1536- or 3456-well formats.   
Despite these advantages, some concerns have been raised, 
such as the requirement for long incubation periods, difficulty 
in antagonist detection due to reporter accumulation and the 
higher potential for false positives because the signal event is 
distal from receptor activation.  Concerns about the long incu-
bation time and accumulation of reporter have been addressed 
through the use of destabilized reporters (available from Pro-
mega).  The higher false positive rate due to the distal signal-
ing event could be partially resolved with by the co-expression 
of a constitutively expressed internal control
[35], so compounds 
nonspecifically affecting gene transcription could be ruled 
out.  Chen et al demonstrated that by combining pathway-
specific reporter assays, all four major G protein subfamilies 
and downstream pathways could be studied in one luciferase 
reporter assay format.  This combination could help establish 
receptor-G protein profiles for specific receptors and aid drug 
screening for pathway-specific GPCR modulators
[34].
Generic G-protein independent functional assays
Receptor internalization assay
The concept of the GPCR internalization assay is based on the 
common phenomenon of GPCR desensitization, which has 
been demonstrated for numerous GPCRs (reviewed in
[36]).   
In the desensitization process, GRKs phosphorylate agonist-
activated GPCRs on specific serine and threonine residues, 
and cytosolic β-arrestins are recruited to the cell membrane by 
GRK-phosphorylated GPCRs.  β-Arrestins uncouple GPCRs 
from their cognate G proteins and target the receptors to 
clathrin-coated pits for endocytosis.  With the development of 
image-based, high-content screening (HCS) systems, the inter-
nalization of GPCRs is now a quantifiable process.  
To date, most high-throughput, cell-based screens have 
been whole-well cell assays that quantify one molecular event 
or provide a single readout of a complex biological process 
(eg, measurement of intracellular Ca
2+ concentration for Gαq-
coupled GPCR activation) — they have been one-dimensional.   
HCS is a relatively new technology, introduced approximately 
10 years ago, that combines high-resolution fluorescence 
microscopy with automated image analysis (reviewed in
[37]).   
This technology offers multi-dimensional or multi-parametric 
readouts by monitoring various biomolecules labeled with 
different fluorophores.  The multi-parametric data generated 
by HCS can also provide temporal and spatial information 
for biomolecules, thus enabling a more sophisticated under-
standing of responses in the cell after stimulation.  There are 
a few HCS systems currently available; some are based on 
automated epi-fluorescent microscopes, such as the Cellom-
ics ArrayScan
TM Series from Thermo Scientific (http://www.
thermo.com.cn/HCS), while others are equipped with confo-
cal optics, such as the INCell
TM Analyzer 3000 from GE Health-
care and Opera
TM from Evotec Technologies.  More recently, 
the development of a laser-scanning fluorescence microplate 
cytometer, for example, the Acumen
TM Explorer from TTP 
Lab Tech, offers even higher throughput in these multiplexing 
assays.
In contrast to the aforementioned Ca
2+, cAMP and reporter 
assays, the internalization assay is independent of the asso-
ciated G protein subclass or individual GPCR intracellular 
signaling pathway.  Thus, there is no need to have prior 
knowledge of the signaling pathways of a GPCR before using 
this assay.  The internalization assay is particularly useful for 
de-orphaning GPCRs, while the imaging-based GPCR inter-
nalization assays also offer the general advantage of the HCS 
format.  
There are several ways to monitor the internalization pro-
cess of GPCRs.  For GPCRs with known ligands, fluorophore-
labeled specific ligands can be used to detect the internaliza-
tion of the receptors.  Fluorescent ligands have been used since 
the mid-1970s.  When coupled to the growing exploitation of 
imaging-based HCS analysis, it is clear that fluorescent mol-
ecules offer a safer, more powerful and more versatile alterna-
tive to traditional radioligand binding assays
[38].  Another way 
to visualize the internalization of a GPCR is to co-internalize 
a specific antibody, directed either against an extracellular 
domain of the receptor or against an N-terminal epitope tag
[39].   
The primary antibody is co-internalized with the receptor 
upon agonist stimulation and then detected with a fluoro-
phore-labeled secondary antibody.  Considering the cost of 
antibodies and the tedious procedure of immunofluorescent 
staining, this method is commonly used for GPCR signaling 
studies but not large-scale drug screening.  GPCRs tagged 
with fluorescent proteins (GFP or RFP) are the most common 
setup for HCS of receptor internalization (Figure 2) and are 
widely used for receptor deorphanization.  When internal-
ized, these tagged-GPCRs form grain-like objects within the 
cells.  The Spot detector bio-application in the ArrayScan
TM 
system or the granularity analysis module of the INCell
TM 
Analyzer can identify, analyze and quantify these grain-like 
structures
[40, 41].  With the EGFP-tagged GPR120 internalization 
assay, Hirasawa and colleagues de-orphaned this receptor 
and found that unsaturated long-chain free fatty acids activate 
GPR120 and promote GLP-1 secretion
[42].
β-arrestin recruitment assay
β-arrestins are cytosolic proteins that bind to ligand-activated 
GPCRs, uncouple the receptors from G proteins and target 
the receptors to clathrin-coated endocytic vesicles.  β-arrestin 
recruitment is a ubiquitous mechanism of negative regulation 
of GPCR signaling that has been demonstrated for almost all 
GPCRs
[43].  More recently, β-arrestins have themselves been 
shown to act as signaling scaffolds for numerous pathways, 378
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such as c-Src, ERK 1/2, and Akt, in a G protein-independent 
manner
[4].  G protein and β-arrestin pathways were found to 
be distinct and could be pharmacologically modulated inde-
pendently with “biased ligands”
[44].  Therefore, β-arrestin-
based assays are more interesting, potentially providing new 
insights into the functional selectivity (biased agonism) of 
GPCR signaling.  These insights may help eliminate undesir-
able side effects by activating certain pathways but not others.   
Therefore, β-arrestin recruitment assays provide novel, uni-
versal, and G-protein independent ways for GPCR screening 
and drug discovery.  Such assays are particularly useful for 
the screening of Gαi-coupled GPCRs, which traditionally suf-
fer from a small assay window in second messenger detection 
systems, and orphan GPCRs.  
The first commercialized β-arrestin recruitment assay, Trans-
fluor
TM, was originally licensed by Norak Biosciences in 1999 
from Duke University Medical Center and is now available 
from Molecular Devices.  The Transfluor
TM assay is performed 
using GFP-tagged β-arrestin.  The redistribution of diffuse 
β-arrestin-GFP from the cytoplasm to agonist-occupied recep-
tor-containing pits or vesicles can be monitored quantitatively 
with a high content imaging system, such as the INCell
TM Ana-
lyzer, ArrayScan
TM, Acumen
TM or ImageXpress
TM [45–47].  Taking 
advantage of these HCS instruments, the Transfluor
TM assay 
provides robust high-throughput screening for compounds 
targeting GPCRs
[48, 49].  The benefits of this assay include the 
following: (1) no fluorescent dyes or secondary substrates are 
required; (2) the cell imaging assay allows parallel detection 
of putative compound liabilities, such as cytotoxicity; (3) visu-
alization of β-arrestin localization (to the membrane or to the 
vesicles) and (4) multiplexing with the receptor internalization 
assay (Figure 2) and providing additional information regard-
ing drug effect with respect to ligand-induced trafficking.   
Like any other imaging-based assays, to obtain high quality 
images for further software analysis, the cell type used should 
be grown in a monolayer, have good adherence properties and 
have a large cytoplasm-to-nucleus ratio.  Before conducting a 
HTS screening for orphan GPCRs, a ligand independent trans-
location assay (LITe™), which utilizes a constitutively active 
GRK2 to phosphorylate the receptor and initiate GPCR-β-
arrestin interaction, is required to verify that the receptor can 
indeed recruit β-arrestin-GFP after stimulation
[50].
Alternatively, several non-imaging-based β-arrestin recruit-
ment assays, such as Bioluminescence Resonance Energy 
Transfer (BRET), PathHunter
TM technology (DiscoveRx) and 
the Tango
TM assay (Invitrogen), are available.  The BRET 
assay was one of the earliest approaches utilized for assessing 
GPCR-β-arrestin interactions and can be scaled for HTS
[51, 52].   
The receptor of interest is tagged at the C-terminus with a 
fluorescent protein tag (such as eGFP2, GFP10 or YFP) and 
the β-arrestin is tagged with a Renilla luciferase (RLuc) or vise 
versa.  Upon β-arrestin recruitment, the two tags come into 
close proximity and the light emitted from the RLuc reac-
tion excites the GFP, which then emits a detectable signal at 
a higher wavelength (Figure 3A).  BRET is calculated as the 
ratio of the two emissions (GFP/RLuc).  It was reported that 
increased BRET sensitivity can be achieved by using RLuc8/
YPet and RLuc8/RGFP as donor/acceptor couples
[53].
Invitrogen’s Tango™ GPCR Assay System is a platform 
based on a protease-activated reporter gene (Figure 3B).   
β-arrestin is fused to a TEV protease, while GPCR is extended 
at its C-terminus with a protease cleavage site followed by 
the transcription factor Gal-VP16
[54].  Upon GPCR activation, 
protease-tagged arrestin is recruited to the receptor and the 
Gal-VP16 that is fused to the receptor is cleaved and enters 
the nucleus to regulate the transcription of a β-lactamase 
reporter gene.  The β-lactamase catalyzes the cleavage of a 
modified substrate tagged with two fluorophores, and the 
change in FRET signal between these two fluorophores can 
be monitored.  Tango™ GPCR assays have been validated for 
a diverse array of GPCRs, including receptors related to each 
of the major G protein pathways and activated by a variety of 
ligand types
[55, 56].  
The PathHunter
TM assay developed by DiscoveRx utilizes 
enzyme fragment complementation of β-galactosidase and 
subsequent enzymatic activity to measure receptor−β-arrestin 
interactions (Figure 3C).  In this assay, β-arrestin is fused 
to an N-terminal deletion mutant of β-galactosidase that is 
catalytically inactive, and GPCR is tagged at the C-terminus 
with a small (4 kDa) fragment derived from the deleted 
N-terminal sequence of β-galactosidase (ProLink™).  Upon 
GPCR-β-arrestin interaction, the two parts of β-galactosidase 
Figure 2.  Transfluor
TM and receptor internalization assays.  Schematic 
representation of Transfluor
TM β-arrestin recruitment assay multiplexed 
with a receptor internalization assay.  The receptor is tagged at the 
C-terminus with RFP, and β-arrestin is tagged with GFP.  In the resting 
state, the receptor is located on the cell membrane and β-arrestin is 
localized in the cytoplasm (Phase 0).  A few seconds to several minutes 
after stimulation, the receptor is phosphorylated by GRK and β-arrestin 
is recruited to the cell membrane (Phase 1).  β-arrestin binding leads to 
the internalization of the receptor-β-arrestin complex, initially forming 
internalization pits (Phase 2).  For fast-recycling GPCRs, the receptor 
dissociates with β-arrestin and returns to the plasma membrane.  For 
slow-recycling GPCRs, the receptor-β-arrestin complex traffics towards the 
endosome and forms large vesicles (Phase 3).379
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are brought into proximity, which results in the activation 
of the enzyme, cleavage of the substrate and generation of a 
chemiluminescent signal.  Similar to Tango™ GPCR assays, 
PathHunter™ has also been validated for a diverse array of 
GPCRs and is widely accepted in industrial and academic 
drug-screening laboratories
[57, 58].  Both assays also have com-
mercially available, assay-ready cell lines for a large number 
of GPCRs.  There are several advantages in the PathHunter™ 
assay, including a homogeneous assay with enzyme-amplified 
robust signal.  The chemiluminescent signal is also low in 
background and resistant to interference from fluorescent 
compounds.  One disadvantage of this platform is that the 
time window for measurement is limited, so the assay only 
captures a snapshot of β-arrestin-receptor binding during 
the period of substrate incubation.  However, this limitation 
can also be viewed as an advantage when using instruments 
capable of real-time detection to study the kinetics of GPCR-β-
arrestin interaction.  
Label-free whole cell assays
Label-free technologies, which emerged within the past few 
years, have the potential to substantially change some aspects 
of whole-cell assays, including GPCR screening (reviewed 
in
[59]).  Many assays widely employed for GPCR ligand dis-
covery tend to provide reductionist views of cell signaling.   
These assays are extremely robust and have been successfully 
implemented for measuring one particular functional activ-
ity of GPCRs, but often fail to account for the summation of 
events associated with the activation of one or more receptors.   
The emergence of label-free technologies presents a different 
strategy in measuring signal transduction, with integrated or 
cumulative responses rather than the resolution of individual 
events.  Label-free, whole cell assays generally employ a bio-
sensor that converts the summation of ligand-induced changes 
in living cells to optical, electrical, calorimetric, acoustic, mag-
netic or other quantifiable signals.  They can detect changes in 
cellular features including adhesion, proliferation, migration, 
and cell death.  
Most of the label-free instruments available for GPCR 
screening use either an optical or electrical biosensor to detect 
cellular changes after stimulation.  The optical biosensors are 
also called resonant waveguide grating (RWG) biosensors, 
which utilize grating structures embedded in the bottom of 
microtiter plates (Figure 4B).  When illuminated with broad-
band or monochromatic light, these grating surfaces reflect 
a narrow band of light that is characteristic of the refractive 
index near the grating surface.  These instruments can detect 
Figure 3.  Non-imaging-based β-arrestin recruitment assays.  (A) BRET 
assay.  The GPCR is tagged with a RLuc, and β-arrestin is tagged with 
GFP, or vice versa.  Upon β-arrestin recruitment, the two tags come into 
close proximity and the light emitted from the RLuc reaction excites the 
GFP, which then emits a detectable signal at a higher wavelength.  (B) 
Tango
TM assay.  β-arrestin is fused to a protease, while GPCR is extended 
at its C-terminus with a protease cleavage site followed by a transcription 
factor (TF).  Upon β-arrestin recruitment, the TF fused to the receptor 
is cleaved and enters the nucleus to regulate the transcription of a 
reporter gene.  (C) PathHunter
TM assay.  β-arrestin is fused to a deletion 
mutant of β-galactosidase that is catalytically inactive, and GPCR is 
tagged with a small fragment derived from the deleted sequence of the 
enzyme (ProLink™).  Upon GPCR-β-arrestin interaction, the two parts of 
β-galactosidase are brought into close proximity, which results in cleavage 
of the substrate and generation of a chemiluminescent signal.  
Figure 4.  Principles of the biosensors for label-free, whole-cell detection.   
(A) Schematic representation of an electrical biosensor.  Cells are cultured 
on the surface of arrayed gold microelectrodes.  A low AC voltage at 
variable frequencies is applied to the cell layer and both the extracellular 
current and transcellular current are measured.  (B) Schematic represen-
tation of an optical biosensor.  Cells are cultured on the surface of 
the biosensor with an embedded grating structure.  Only the mass 
redistribution within the bottom portion of cells is directly measured.380
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either angle- or wavelength-shift
[60].  The refractive index is 
influenced by the physical properties of the cell layer in con-
tact with the grating surface.  When a GPCR is activated and 
subsequent signal transduction changes the biomolecular 
concentration within an approximately 200 nm range of the 
contact surface, the disturbance in local refractive index can 
be detected as a shift in resonant angle or wavelength.  The 
current optical-based instruments include BIND
TM (SRU Bio-
systems) and Epic
TM (Corning Inc) systems.  Although initially 
designed for in vitro molecular binding assays, both systems 
were successful in studying cell morphological changes and 
GPCR signaling
[61, 62].  
Electrical biosensors, also known as impedance-based bio-
sensors, mainly consist of a substrate, an electrode and a cell 
layer in close contact with the electrode (Figure 4A).  Giaever 
and Keese of GE first reported the use of impedance to mea-
sure cellular processes
[63].  In their early studies, fibroblasts 
cultured on thin-film gold electrodes were found to impede 
the flow of a very weak alternating current.  The impedance 
change could be monitored in real-time, and the fluctuation 
of impedance was dependent on ATP concentration and actin 
polymerization, and was thus linked to cellular motion
[64].   
Since then, electrical-based detections have been applied to 
study a wide variety of cellular events, including cell adhe-
sion and spreading
[65], cell morphological changes
[66], and cell 
death
[67].  It is now generally accepted that the impedance 
value is the sum of cellular events, including the relative den-
sity of cells over the electrode surface and the relative adher-
ence of these cells.  
Applied Biophysics launched ECIS
TM, the first commercially 
available instrument for electrical-based whole cell detection 
with high-throughput capability (up to 96-well detection), in 
1995.  The more recently available (2008) xCELLigence
TM Sys-
tem from Roche Applied Science and ACEA Biosciences is also 
built to fit into cell culture incubators and to measure long-
term cellular responses that occur over hours to days.  Both 
systems have been used to detect GPCR activity for hours
[68, 69].   
A more high-throughput system, CellKey
TM, was developed 
by MDS Analytical Technologies, which is designed to detect 
acute cellular responses in 96- and 384-well formats.  
Based on both the CellKey
TM and Epic
TM systems, scien-
tists observed distinct response profiles depending on the 
G-protein pathway activated
[62, 70, 71].  Several studies compared 
the Epic
TM system and traditional Ca
2+ or cAMP assays using 
CHO cells expressing the muscarinic M2, M3 or dopamine D3 
receptors.  Most of the results from the Epic
TM were consistent 
with data from cAMP or Ca
2+ readouts with few exceptions, 
and the Epic
TM was found to detect weak activity that was 
not observed with the label-based assays
[72, 73].  Many studies 
with GPCR ligand sets also demonstrated similar rank-order 
potency values between CellKey
TM impedance and traditional 
Ca
2+ or cAMP assays
[74–76].  
The sensitivity, precision and high-throughput of some 
label-free instruments warrant their use in HTS, although the 
cost of consumables might limit broader application.  These 
systems have also been used for ligand selectivity studies
[76–78], 
endogenous receptor profiling in cell lines commonly used in 
drug discovery
[62, 74, 77], systemic cell biology studies of GPCR 
signaling
[77, 79], and many other aspects of GPCR research.  Like 
any other functional assay, label-free, whole cell assays are 
also prone to false positives.  Another unique problem associ-
ated with label-free systems is the possibility that signaling 
through multiple pathways with opposing effects may cause 
a lack of overall response, resulting in a false negative out-
come
[70].  In combination with traditional assays, biosensor-
based label-free methods have a promising future and should 
further strengthen the role of GPCRs in drug discovery and 
development.
Receptor dimerization assay
Many, but perhaps not all
[80], GPCRs interact with each other 
at the plasma membrane to form dimers, oligomers or even 
higher-order complexes.  The dimerization of GPCRs can be 
observed early after biosynthesis and profoundly impacts 
receptor pharmacology and signaling (reviewed in
[81]).  For 
class C GPCRs, heterodimerization is obligatory for recep-
tor function.  Many class A GPCRs, however, can function as 
homodimers when individually expressed in cells, and het-
erodimerization between class A GPCRs may lead to distinct 
and unique signaling properties even when stimulated with 
the same ligand, a phenomenon termed “heteromer-directed 
signaling specificity.” Such phenomena are believed to be 
involved in the physiological roles of GPCRs and in disease-
specific dysregulation of a receptor effect
[82, 83].  Therefore, 
compounds that specifically target GPCR heterodimers or 
affect receptor dimerization may have the potential to achieve 
specific therapeutic effects
[84].  As a result, there is consider-
able interest in designing assays to assess the effect of com-
pounds on GPCR dimerization.  Various technologies have 
been established to monitor receptor dimerization, including 
resonance energy transfer approaches (FRET or BRET) and the 
recently developed PathHunter
TM GPCR dimerization system 
(DiscoveRx) and Tag-lite
TM GPCR dimer assay (Cisbio).
In commonly used FRET or BRET-based approaches, donor 
and acceptor molecules are genetically fused to the C-terminus 
of GPCRs, which are overexpressed in the cells (Figure 5A).   
Resonance energy transfer occurs when donor and acceptor 
molecules are brought into close proximity as a consequence 
of GPCR dimerization (reviewed in
[85, 86]).  However, one 
limitation of such traditional FRET and BRET assays is that 
in the overexpression system, resonance energy transfer can 
also occur within the intracellular compartments such that 
it is difficult to demonstrate a specific signal resulting only 
from a direct interaction of proteins at the cell surface.  In 
addition, low signal-to-noise ratio resulting from the intrinsic 
fluorescence background of a cell and the overlap between 
the emission spectra of FRET donors and acceptors is another 
limitation of the commonly used resonance energy transfer 
techniques.
The GPCR dimerization assay with Tag-lite
TM is a method 
combining TR-FRET with SNAP-tag
TM technology (Cisbio), 
enabling quantitative analysis of protein-protein interactions 381
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at the surface of living cells in a 96- or 384-well format.  In this 
assay, GPCRs are tagged with either a SNAP- or CLIP-tag at 
the N-terminus, which can be subsequently labeled with their 
corresponding cell-impermeable substrates carrying appropri-
ate TR-FRET-compatible fluorophores, typically using terbium 
cryptate as a donor and a green or red fluorescent molecule as 
an acceptor (Figure 5B).  Several possible dimer combinations 
exist in this assay: 1/4 of the dimers contain both receptors 
labeled with the donor, 1/4 of the dimers contain both recep-
tors labeled with the acceptors, and 1/2 of the dimers contain 
one receptor labeled with the donor and one receptor labeled 
with the acceptor.  Only the last fraction will emit the FRET 
signal
[87].  This assay was validated with well-known GPCR 
dimers and the oligomeric assembly of both class A and class 
C GPCRs was confirmed
[88].
The PathHunter
TM GPCR dimerization system from 
DiscoveRx is another platform for GPCR heterodimeriza-
tion analysis.  Cell lines utilized in the previously described 
PathHunter
TM β-arrestin recruitment assay can be used as 
the starting material.  In these cell lines, β-arrestin is fused 
to the larger portion of the β-galactosidase enzyme accep-
tor, and the smaller 42-amino acid ProLink™ tag is attached 
to one of the GPCR targets.  A second untagged GPCR can 
be introduced into the cells and the transactivation effects 
of the untagged GPCR on the ProLink™-tagged GPCR can 
be measured by the recruitment of β-arrestin to the tagged-
GPCR using PathHunter detection reagents (Figure 5C).  The 
transactivation strength can be estimated as a ratio between 
the cellular response to the agonist of the untagged GPCR and 
the response to the agonist of Prolink™-GPCR.  The assay can 
be used to investigate the interaction between GPCR pairs, as 
well as screen for compounds that modulate GPCP activity 
through enhancing or disrupting GPCR heterodimerization in 
a 384-well format (http://www.discoverx.com/documents/
DRx_poster_Heterodimer_DOT09_REV1.pdf).
In silico drug discovery
GPCR drug discovery usually relies on HTS for hit identifica-
tion.  However, with the development and maturation of com-
putational methods for drug discovery, HTS may be comple-
mented by in silico screening.  This combination of approaches 
will reduce both time and cost through reducing the number 
of compounds to be experimentally tested and increase the 
probability of identifying novel lead compounds.  Both ligand-
based and structure-based methods for in silico screening have 
been successfully applied to GPCR drug discovery.  
Structure-based screening requires reliable 3D structures for 
the target protein, which poses a challenge for GPCRs because 
of the heterogeneity of this receptor family and the lack of 
crystallographic data.  Until 2008, the only available GPCR 
structure was that of bovine rhodopsin
[89].  In the last few 
years, a number of different technological developments
[90] 
have resulted in the structures of several new GPCRs, includ-
ing β2 adrenergic receptor
[91], A2a adenosine receptor
[92], 
CXCR4 chemokine receptor
[93], dopamine D3 receptor
[94] and 
histamine H1 receptor
[95].  Additionally, the first structure of 
a signal transduction complex (β2 adrenergic receptor and 
Gαs) has also been reported
[96].  Nevertheless, the relatively 
limited 3D information for GPCRs is an obstacle for structure-
based drug discovery.  In the absence of crystal structures, 
both homology modeling and ab initio techniques have been 
applied to model the 3D structures of GPCRs and used for in 
silico screening (reviewed in
[97, 98]).  
When a crystal structure of the targeted protein is not avail-
able and reliable modeling is not feasible, a problem common 
to many GPCRs, ligand-based drug discovery methods remain 
the major computational approach for the analysis of the 
growing data sets for GPCR ligands.  Ligand-based screening 
is highly efficient and can be productive with sufficient infor-
mation on known ligands.  Incorporating ligand information 
with homology modeling has also been applied with good 
results (reviewed in
[97, 99, 100]).  
Conclusion
Choosing the right primary HTS assay for GPCRs, one of the 
most important protein families for therapeutic targeting, is 
critical in early drug discovery.  With the availability of all the 
aforementioned assays, a few important things must also be 
Figure 5.  Receptor dimerization assays.  (A) BRET dimerization assay.   
GPCRs are tagged with a RLuc donor and a GFP acceptor.  Upon receptor 
dimerization, the two tags come into close proximity and energy transfer 
occurs.  (B) Tag-lite
TM dimerization assay.  GPCRs are tagged with either a 
SNAP- or CLIP-tag at the N-terminus, which can be subsequently labeled 
with their corresponding cell-impermeable substrates carrying appropriate 
TR-FRET-compatible fluorophores.  (C) PathHunter
TM heterodimerization 
assay.  β-arrestin is fused to the larger portion of a β-galactosidase 
enzyme acceptor, and the ProLink™ tag is attached to one of the GPCR 
targets.  A second untagged GPCR can be introduced into the cells, and 
the transactivation effects of the untagged GPCR on the ProLink™-tagged 
GPCR can be measured by the recruitment of β-arrestin to the tagged-
GPCR using PathHunter detection reagents.382
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considered.  First, the choice of cell line for GPCR expression 
might affect assay development because such cell line might 
lack correct post-translational modification and dimerization 
of GPCRs, and the expression of important signaling mol-
ecules.  Second, the level of GPCR expression also needs to be 
carefully monitored because significant overexpression might 
lead to ligand-independent signaling and shifts in G protein 
coupling.  Third, the functional selectivity (biased signaling) 
of ligands might complicate the screening process.  Assays 
based on one signaling pathway might miss potentially valu-
able compounds acting on other pathways.  Therefore, mul-
tiplexing of assays or a summed readout should always be 
considered.  With the advancement of high-content imaging 
and label-free, whole cell technologies, new GPCR functional 
assays might provide more comprehensive and physiologi-
cally relevant information on lead compounds and might 
improve the success rate in drug discovery.  
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